Novel Strategies: Combining Systemic and Local Therapies
February 2nd 2023Ghassan Abou-Alfa, MD, Robert Lewandowski, MD, FSIR, and Amit Singal, MD discuss potential novel combination therapies including immune checkpoint inhibitors plus tyrosine kinase inhibitors plus local-regional therapeutic strategies.
Read More
Real-World Evidence on Use of Immune Checkpoint Inhibitor Combinations and Clinical Trial Endpoints
January 26th 2023Experts in liver cancer treatment provide insight on real-world trials of immune checkpoint inhibitor combinations in HCC and opine on trial endpoints when immune therapy is utilized.
Read More
Dr. Abou-Alfa on the FDA Approval of Cabozantinib in HCC
January 20th 2019Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses how the FDA approval of cabozantinib (Cabometyx) is likely to shake up the landscape and impact sequencing for patients with hepatocellular carcinoma (HCC).
Read More